Drug updated on 4/17/2024
| Dosage Form | Injection (intravenous; 100 mg/5 mL, 400 mg/20 mL [20 mg/mL] in a single-dose vial) |
| Drug Class | Epidermal growth factor receptor antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): in combination with FOLFOX for first-line treatment.
- Indicated as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.
Summary
- Panitumumab (Vectibix) is indicated for the treatment of wild-type RAS metastatic colorectal cancer, either in combination with FOLFOX for first-line treatment or as monotherapy following disease progression after prior chemotherapy. It has been found to significantly increase objective response rates and R0 resection rates when combined with triplet-drug chemotherapy.
- Four studies focused on the application of Vectibix in treating metastatic colorectal cancer. These studies highlighted both its effectiveness and safety profile compared to other drugs used for this condition.
- Common grade 3 and 4 adverse events associated with panitumumab include diarrhea, neutropenia, and skin toxicity. Despite these side effects, it is considered very effective, especially when combined with a regimen like FOLFOXIRI.
- In terms of efficacy among different patient subgroups, panitumumab shows significant improvement in patients carrying wild-type KRAS gene status but does not affect those with mutant KRAS in terms of objective response or disease progression rate.
- When comparing fatal adverse events across targeted drugs including bevacizumab, cetuximab, and panitumumab; no significantly increased risks were observed, suggesting a comparable safety profile among these agents. However, a slightly higher risk was noted for cetuximab in adjuvant treatment settings based on relative risks for fatal adverse events.
- Patients receiving combination therapy involving anti-EGFR agents such as Vectibix might experience higher rates of resection during metastasis, indicating potential benefits related to surgical outcomes while maintaining long-term safety profiles similar to other treatments currently available.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vectibix (panitumumab) Prescribing Information. | 2021 | Amgen Inc. Thousand Oaks, CA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) – a real-life data report 2013-2018. | 2023 | Radiology and Oncology |
| Tumor biomarker testing for metastatic colorectal cancer: a Canadian consensus practice guideline. | 2022 | Therapeutic Advances in Medical Oncology |